#Japan #Tokyo #Kyowa Kirin #Rocatinlimab #EADV 2025

Kyowa Kirin to Present Findings on Rocatinlimab at EADV 2025

Kyowa Kirin Co., Ltd. has announced exciting developments regarding the Phase 3 ROCKET IGNITE trial, also known as KHK4083, which investigates the efficacy and safety of rocatinlimab, an innovative treatment aimed at patients suffering from moderate to severe atopic dermatitis (AD). The findings will be showcased at the upcoming European Academy of Dermatology and Venereology (EADV) Annual Meeting in Paris, France, scheduled from September 17-20, 2025.

About the Presentation

On Friday, September 19, renowned dermatologist Dr. Emma Guttman-Yassky will present the abstract entitled "Efficacy and Safety of OX-40 Receptor Targeting with Rocatinlimab in Moderate-to-Severe Atopic Dermatitis - Results from the Phase 3 ROCKET-IGNITE Trial." This presentation is poised to shed light on a pivotal development in treating a condition that has long remained challenging for both patients and healthcare providers alike.

The presentation will take place from 4:40 PM to 4:50 PM CEST at the Paris Convention Centre, specifically in Room W05-W06, and is expected to attract considerable interest due to the growing need for effective interventions in chronic inflammatory conditions like atopic dermatitis.

Understanding Atopic Dermatitis

Atopic dermatitis is characterized by symptoms including itchy, inflamed skin, which can lead to severe discomfort and a significant decline in the quality of life. This condition affects approximately 15-20% of children and about 10% of adults. The chronic nature of AD, along with unpredictable flare-ups, underscores the importance of effective treatments.

The pathogenic pathway in atopic dermatitis is heavily influenced by T-cell imbalances, particularly through the activity of OX40 receptor-positive T cells, which exacerbate inflammatory responses. Rocatinlimab aims to target the OX40 receptor directly, presenting a promising avenue for therapeutic intervention by potentially restoring T-cell balance and reducing inflammation.

The ROCKET Phase 3 Program

The ROCKET program encompasses a thorough clinical examination of rocatinlimab, comprising eight studies aimed at validating its safety and efficacy across diverse patient demographics. By focusing on adults and adolescents with moderate to severe atopic dermatitis, this program seeks to pave the way for more targeted and effective treatments.

Rocatinlimab: A New Horizon in Treatment

Rocatinlimab is a human monoclonal antibody designed to rebalance T-cell activity by inhibiting pathogenic T cells through targeted OX40 receptor blockade. The unique mechanism of action of rocatinlimab could revolutionize the approach to treating not only atopic dermatitis but also other conditions linked to T-cell dysregulation, like prurigo nodularis and uncontrolled asthma.

As part of a collaborative effort, the initial discovery of rocatinlimab stemmed from a partnership between Kyowa Kirin and the La Jolla Institute for Immunology. This collaboration emphasizes both companies' commitment to advancing medical science and improving patient care.

Looking Ahead

Kyowa Kirin is dedicated to developing life-changing therapies that address unmet medical needs. As the company prepares to present its findings at EADV 2025, the hope is to foster broader discussions on innovative treatment options and ultimately enhance patient outcomes in chronic inflammatory diseases.

In addition to its focus on atopic dermatitis, rocatinlimab is currently being evaluated for a variety of conditions with T-cell imbalances. The future of this investigational therapy holds promise, but its efficacy and safety remain under clinical investigation, pending further results and evaluations by regulatory authorities, including the U.S. FDA.

For more information on Kyowa Kirin’s commitment to drug discovery and biotechnology innovation, please visit their official website at Kyowa Kirin.